How to succeed in the business of biotech patentability

The US Supreme Court has thrown down the gauntlet for patent eligibility in the biotechnology field. In spite of (or due to) their significant contributions to medicine, Mayo v Prometheus, Association for Molecular Pathology v Myriad Genetics, and Ariosa Diagnostics v Sequenom exemplify the harsh reality of recent changes in defining patent-eligible subject matter. These recent changes have left companies wondering how best to protect their products.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Penile implant maker’s $17m trade secret award unravels

20 April 2026 The maker of a cosmetic penile implant has suffered at the Federal Circuit, after a ruling said its trade secrets claims are not protectable while leaving a counterfeiting finding intact.

Americas

Appeals court eases Teva’s headache with reversal

17 April 2026 A ruling that invalidated three of Teva's headache treatment patents has been thrown out, sending a long-running case back to the lower court.

Americas

Cancer drug researcher hit with suit over mutation-targeting tools

16 April 2026 The Cambridge biotech is accused of infringing six patents covering technologies used to target drug-resistant cancer mutations.